Y-Biologics Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:40
Jan 15
Jan 15
Y-Biologics targets Keytruda-resistant cancer
Y-Biologics is developing next-generation immuno-oncology antibodies combining PD-1/PD-L1 bispecific and cytokine engineering to address the 70% of patients who do not respond to Keytruda; AACR in April is a major catalyst.
MED
About Y-Biologics Investor Commentary
Across the available history and selected sources, Buzzberg tracks Y-Biologics across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lee Kyung-ho.